PDF-Paediatric Antiretroviral Drug Optimization PADO Meeting 4

1012December2018GenevaSwitzerlandMeetingreportAnnex 1 Meeting agendaDay 1 Monday 10 December 201813301345Registration13451415Welcome and introductionsMeg Doherty Overview of meeting objectives and age. in the Recovery Room. Michelle McNamara. Proposed Learning. Paediatric Emergencies . . A.B.C.D.E. A. irway. B. reathing. C. irculation. D. isability (depressed consciousness, unresponsiveness).. E. What’s different about paediatric prescribing. Children are just . small adults. NOT!. Vary in their developmental stages. Pre-term, neonates, infants, children, adolescents. Dynamic anatomy and physiology. . PN Harden, BMJ June 2012. M Graham-Brown. UHL . Jan 2014. What’s the problem?. ESRD is rare in paediatrics (9-50 ppm). Transplantation is the treatment of choice, as in addition to being the best ‘treatment’ for renal failure, it restores growth and pubertal development in children. NCA (nurse controlled analgesia) chart. Implementation Education. A presentation prepared by the Office of Kids and Families . in association with the Agency of Clinical Innovation Pain Management Network . Module 10:. Pharmacovigilance. Background – definitions. Timeline of pharmacovigilance for a drug from development (pre-market) to post-marketing use. Burden of adverse drug reactions in children. Number of pharmacoepidemiological safety studies in children (Osokogu et al, 2016). Sean Schafer MD. May 31, 2012. Three Studies in One. Evaluating antiretroviral drug resistance surveillance in Oregon. Determining frequency of transmitted antiretroviral drug resistance, comparing to U.S.. www.who.int PADO TB 1: Process and main outcomes Dr. Malgorzata Grzemska , GTB/TSC PADO - TB 1 report back webinar, 27/2//2019 Outline • Some data: TB in children • WHO policies • PADO TB obj First Paediatric Antituberculosis Drug Optimization Meeting (PADO - TB 1) Date: 14 - 15 February 2019 Meeting room CDS65, fourth floor of the WHO D - building/UNAIDS building, Geneva, Switzerland 2 E NOTEMake sure the combined number and length of all named services advertisedin the PADO packet does not exceed the MTU size of the PPPoE underlying interfaceTo enable advertisement of named services PADO-Dr Martina Penazzato MD MSc PhDPaediatricHIV lead HIV and Hepatitis Department World Health Organization Geneva SwitzerlandThe development of pediatric products lags unacceptably behind that of a Enp. teaching. 22/12/21. Zoe . smeed. Aims/objectives. EXAMINATION TIPS. Critol. Xr. interpretation. Common presentations - #, DISLOCATIONS, PULLED ELBOW. PAEDS TIPS. EXAMINATION. Look – feel - move. A5173 Study. Intensive . Enfuvirtide. -containing Antiretroviral Therapy . A5173: . Study Design. Source: Gandhi RT, et al. . J . Infect. . Dis. . . 2010;201(2. ):293-6.. Enfuvirtide. +. TDF + (FTC or 3TC) +. Ben Powell. Nadine Edwards. Outline. DELTA GP. Simulation. Anaphylaxis definition. GP management of anaphylaxis. Available resources. Questions. DELTA GP. Collaboration between WMHHS and DD/WM PHN. Delivering in-situ emergency simulation training in GP clinics. Replacement Therapy. ANZDATA Registry 46. th. Annual Report. Data to 31-Dec-2022. Chapter 12 - Graphs. Figure 12.1.1 Incidence of KRT - Age 0-17 Years - Australia. Figure 12.1.2 Incidence of KRT - Age 0-17 Years - New Zealand.